1458062-06-0

Upstream product

• 865626-96-6 (±)-methyl 2-(1-benzylpiperidin-4-yl)-3-hydroxy-3-(2-nitrophenyl)propanoate 
• 865626-97-7 (±)-3-(1-benzylpiperidin-4-yl)-4-hydroxy-3,4-dihydroquinolin-2(1H)-one 
• 865626-98-8 3-(1-benzylpiperidin-4-yl)quinolin-2(1H)-one 
• 205058-78-2 3-(piperidin-4-yl)quinolin-2(1H)-one 
• 912463-38-8 4-nitrophenyl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate 
• 1458062-05-9 (±)-1-(7-benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethanol 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 247259-33-2 methyl 2-(1-benzylpiperidin-4-yl)acetate 
• 206558-34-1 C₁₅H₁₉NO₂ 
• 7693-46-1 4-Nitrophenyl chloroformate 
• 1458062-04-8 1-(7-benzyl-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethanone 
• 1458062-03-7 (±)-diphenyl (7-benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazin-3-yl)(phenylamino)methylphosphonate 
• 165894-25-7 C₁₄H₁₅N₃O 
• 165894-09-7 7-benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine 

Downstream Products

• 1458062-07-1 (±)-1-(7-cyclohexyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate 
• 1458062-08-2 (±)-1-(7-benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

TETRAHYDROIMDIDAZOPYRAZINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS

The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the t

Preparation of imidazoles as potent calcitonin gene-related peptide (CGRP) antagonists

Several new potent CGRP receptor antagonists have been prepared in which the amide bond of lead compound 1 has been replaced by bioisosteric imidazole moieties. Substitution at N-1 of the imidazole was optimized to afford compounds with comparable potency